Table 1.

Patient characteristics and treatment.

	Percent of Patients (n = 47)
Age (years): Median 72 (63–84)
60–69 70–79 >80	36.2% (17) 48.9% (23) 14.9% (7)
Race
White Black Other	48.9% (23) 38.3% (18) 12.8% (6)
Time from TURP to SBRT
<12 mon 1–5 yrs 5–10 yrs >10 years Unknown	14 12 6 7 8
# of TURP procedures
1 2 >3	87.2% (41) 10.6% (5) 2.1% (1)
Prostate volume (cc)	Median 42 (11.6–140)
Pre-treatment PSA (ng/ml): Median 6.5 (1.8–17)
<10 >10 and <20	78.7% (37) 21.3% (10)
T stage
T1b–T2a T2b–T2c	80.9% (38) 19.1% (9)
Gleason score
6 7 8–9	29.8% (14) 55.3% (26) 14.9% (7)
Charlson comorbidity Index
0 1 >2	27.7% (13) 10.6% (5) 61.7% (29)
Risk group (D'Amico)
Low Intermediate High	25.5% (12) 59.6% (28) 14.9% (7)
Hormone therapy
Yes No	36.2% (17) 63.8% (30)
Anticoagulation
Anticoagulation No anticoagulation	40.4% (19) 59.6% (28)
SBRT dose
35 36.25	57.4% (27) 42.6% (20)